ArticleGalen medical journal2025
Evaluation of Effectiveness of Bio-Micro Injection in Treating Alopecia Universalis: A Non-Randomized Interventional Study : Mesotherapy in Treating Alopecia Universalis.
Article in Galen medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alopecia areata (AA) is an autoimmune disorder causing non-scarring hair loss, ranging from patchy baldness to total body hair loss (alopecia universalis, AU). AA significantly impacts health-related quality of life. While mesotherapy has shown potential as a localized therapy, its efficacy in AU remains understudied. This study aims to assess the therapeutic impact of mesotherapy in a substantial cohort of 2,000 patients diagnosed with alopecia universalis at Dr. Shirzad Clinic between 2020 and 2024, thereby providing valuable insights into its potential as a treatment modality. Materials and Methods: We conducted a non-randomized interventional study on 2,000 alopecia universalis patients across four treatment groups. Participants were divided into four treatment groups: one group received BMI alone, another received a combination of BMI and JAK inhibitors, the third group received only JAK inhibitors, and the fourth group was treated with a combination of BMI, JAK inhibitors, and adalimumab. All of these drugs were administered through mesotherapy techniques. They received the treatment once a month, for a year. Outcomes, including scalp hair regrowth and patient satisfaction, were assessed monthly over a year. Comorbidities were managed to prevent confounding effects. Results: A total of 2000 patients participated in this study, with an average age of 26.82 ±1.84 years. Treatment responses varied across groups, with children showing the highest success rates. In Group 1 (BMI only), 20% responded positively. Group 2 (BMI + JAK inhibitors) had a 30% had favorable outcomes. Group 3 (JAK inhibitors only) showed a 34% response rate. The combination treatment in Group 4 resulted in the highest success rate, with 42% of participants responding positively. Conclusion: This study highlights the unique contribution of mesotherapy, particularly when combined with systemic treatments such as BMI, JAK inhibitors, and adalimumab, as an effective and well-tolerated option for alopecia universalis. The large sample size and innovative application of mesotherapy enhance drug delivery, improve treatment outcomes, and reduce systemic side effects, underscoring its potential as a valuable treatment strategy for this challenging condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.